ReP USP - Resultado da busca

Artigo de periodico
Distinct urinary glycoprotein signatures in prostate cancer patients (2018)
Kawahara, Rebeca ; Ortega, Fabio; Rosa-Fernandes, Livia ; Guimarães, Vanessa; Quina, Daniel; Nahas, Willian; Schwämmle, Veit ; Srougi, Miguel ; Leite, Katia Ramos Moreira ; Thaysen-Andersen, Morten ; Larsen, Martin R. ; Palmisano, Giuseppe
Fonte: OncoTarget. Unidades: FM, ICB
Assuntos: PARASITOLOGIA, GLICOPROTEÍNAS, NEOPLASIAS, PRÓSTATA, BIOMARCADORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KAWAHARA, Rebeca et al. Distinct urinary glycoprotein signatures in prostate cancer patients. OncoTarget, 2018Tradução . . Disponível em: https://doi.org/10.18632/oncotarget.26005. Acesso em: 26 out. 2025.
APA
Kawahara, R., Ortega, F., Rosa-Fernandes, L., Guimarães, V., Quina, D., Nahas, W., et al. (2018). Distinct urinary glycoprotein signatures in prostate cancer patients. OncoTarget. doi:10.18632/oncotarget.26005
NLM
Kawahara R, Ortega F, Rosa-Fernandes L, Guimarães V, Quina D, Nahas W, Schwämmle V, Srougi M, Leite KRM, Thaysen-Andersen M, Larsen MR, Palmisano G. Distinct urinary glycoprotein signatures in prostate cancer patients [Internet]. OncoTarget. 2018 ;[citado 2025 out. 26 ] Available from: https://doi.org/10.18632/oncotarget.26005
Vancouver
Kawahara R, Ortega F, Rosa-Fernandes L, Guimarães V, Quina D, Nahas W, Schwämmle V, Srougi M, Leite KRM, Thaysen-Andersen M, Larsen MR, Palmisano G. Distinct urinary glycoprotein signatures in prostate cancer patients [Internet]. OncoTarget. 2018 ;[citado 2025 out. 26 ] Available from: https://doi.org/10.18632/oncotarget.26005
Artigo de periodico
MiR-223-5p works as an oncomiR in vulvar carcinoma by TP63 suppression (2016)
Maia, Beatriz de Melo; Rodrigues, Iara Santana; Akagi, Erica Mie; Amaral, Nayra Soares do; Ling, Hui; Monroig, Paloma; Soares, Fernando Augusto; Calin, George Adrian; Rocha, Rafael Malagoli
Fonte: OncoTarget. Unidade: FO
Assuntos: CARCINOMA, GENITÁLIA FEMININA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MAIA, Beatriz de Melo et al. MiR-223-5p works as an oncomiR in vulvar carcinoma by TP63 suppression. OncoTarget, 2016Tradução . . Disponível em: https://doi.org/10.18632/oncotarget.10247. Acesso em: 26 out. 2025.
APA
Maia, B. de M., Rodrigues, I. S., Akagi, E. M., Amaral, N. S. do, Ling, H., Monroig, P., et al. (2016). MiR-223-5p works as an oncomiR in vulvar carcinoma by TP63 suppression. OncoTarget. doi:10.18632/oncotarget.10247
NLM
Maia B de M, Rodrigues IS, Akagi EM, Amaral NS do, Ling H, Monroig P, Soares FA, Calin GA, Rocha RM. MiR-223-5p works as an oncomiR in vulvar carcinoma by TP63 suppression [Internet]. OncoTarget. 2016 ;[citado 2025 out. 26 ] Available from: https://doi.org/10.18632/oncotarget.10247
Vancouver
Maia B de M, Rodrigues IS, Akagi EM, Amaral NS do, Ling H, Monroig P, Soares FA, Calin GA, Rocha RM. MiR-223-5p works as an oncomiR in vulvar carcinoma by TP63 suppression [Internet]. OncoTarget. 2016 ;[citado 2025 out. 26 ] Available from: https://doi.org/10.18632/oncotarget.10247
Artigo de periodico
Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation (2016)
Marcatto, Leiliane Rodrigues; Sacilotto, Luciana; Darrieux, Francisco Carlos da Costa; Hachul, Denise Tessariol; Scanavacca, Maurício Ibrahim; Krieger, Jose Eduardo; Pereira, Alexandre Costa; Santos, Paulo Caleb Junior Lima
Fonte: OncoTarget. Unidade: FM
Assuntos: REGRESSÃO LINEAR, ESTUDOS RETROSPECTIVOS, FIBRILAÇÃO ATRIAL, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MARCATTO, Leiliane Rodrigues et al. Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation. OncoTarget, v. 7, n. 34, p. 54194-54199, 2016Tradução . . Disponível em: https://doi.org/10.18632/oncotarget.10944. Acesso em: 26 out. 2025.
APA
Marcatto, L. R., Sacilotto, L., Darrieux, F. C. da C., Hachul, D. T., Scanavacca, M. I., Krieger, J. E., et al. (2016). Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation. OncoTarget, 7( 34), 54194-54199. doi:10.18632/oncotarget.10944
NLM
Marcatto LR, Sacilotto L, Darrieux FC da C, Hachul DT, Scanavacca MI, Krieger JE, Pereira AC, Santos PCJL. Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation [Internet]. OncoTarget. 2016 ; 7( 34): 54194-54199.[citado 2025 out. 26 ] Available from: https://doi.org/10.18632/oncotarget.10944
Vancouver
Marcatto LR, Sacilotto L, Darrieux FC da C, Hachul DT, Scanavacca MI, Krieger JE, Pereira AC, Santos PCJL. Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation [Internet]. OncoTarget. 2016 ; 7( 34): 54194-54199.[citado 2025 out. 26 ] Available from: https://doi.org/10.18632/oncotarget.10944
Artigo de periodico
AHNAK enables mammary carcinoma cells to produce extracellular vesicles that increase neighboring fibroblast cell motility (2016)
Silva, Thaiomara Alves; Smuczek, Basílio; Valadão, Iuri Cordeiro; Dzik, Luciana Machado; Iglesia, Rebeca Piatniczka; Cruz, Mário Costa; Pereira, André Zelanis Palitot; Siqueria, Adriane Sousa de; Serrano, Solange Maria de Toledo; Goldberg, Gary S; Jaeger, Ruy Gastaldoni ; Freitas, Vanessa Morais
Fonte: OncoTarget. Unidade: ICB
Assuntos: CARCINOMA, TUMOR CARCINOIDE, FIBROBLASTOS, ONCOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Thaiomara Alves et al. AHNAK enables mammary carcinoma cells to produce extracellular vesicles that increase neighboring fibroblast cell motility. OncoTarget, v. 7, n. 31, p. 49998-50016, 2016Tradução . . Disponível em: https://doi.org/10.18632/oncotarget.10307. Acesso em: 26 out. 2025.
APA
Silva, T. A., Smuczek, B., Valadão, I. C., Dzik, L. M., Iglesia, R. P., Cruz, M. C., et al. (2016). AHNAK enables mammary carcinoma cells to produce extracellular vesicles that increase neighboring fibroblast cell motility. OncoTarget, 7( 31), 49998-50016. doi:10.18632/oncotarget.10307
NLM
Silva TA, Smuczek B, Valadão IC, Dzik LM, Iglesia RP, Cruz MC, Pereira AZP, Siqueria AS de, Serrano SM de T, Goldberg GS, Jaeger RG, Freitas VM. AHNAK enables mammary carcinoma cells to produce extracellular vesicles that increase neighboring fibroblast cell motility [Internet]. OncoTarget. 2016 ; 7( 31): 49998-50016.[citado 2025 out. 26 ] Available from: https://doi.org/10.18632/oncotarget.10307
Vancouver
Silva TA, Smuczek B, Valadão IC, Dzik LM, Iglesia RP, Cruz MC, Pereira AZP, Siqueria AS de, Serrano SM de T, Goldberg GS, Jaeger RG, Freitas VM. AHNAK enables mammary carcinoma cells to produce extracellular vesicles that increase neighboring fibroblast cell motility [Internet]. OncoTarget. 2016 ; 7( 31): 49998-50016.[citado 2025 out. 26 ] Available from: https://doi.org/10.18632/oncotarget.10307
Artigo de periodico
Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model (2016)
Souza, Jean Gabriel de; Morais, Katia L. P.; Anglés-Cano, Eduardo; Boufleur, Pamela; Mello, Evandro Sobroza de; Maria, Durvanei Augusto; Origassa, Clarice Silvia Taemi; Zampolli, Hamilton de Campos; Câmara, Niels Olsen Saraiva ; Berra, Carolina Maria; Bosch, Rosemary Viola Bosch; Chudzinski-Tavassi, Ana Marisa
Fonte: OncoTarget. Unidade: ICB
Assuntos: NEOPLASIAS RENAIS, NEOPLASIAS PULMONARES, ADENOCARCINOMA, AMBLYOMMA CAJENNENSE, CARRAPATOS, GLÂNDULAS SALIVARES, MEDICAMENTO, METÁSTASE NEOPLÁSICA, APOPTOSE, IMUNOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, Jean Gabriel de et al. Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model. OncoTarget, v. 7, n. 38, p. 62255-62266, 2016Tradução . . Disponível em: https://doi.org/10.18632/oncotarget.11555. Acesso em: 26 out. 2025.
APA
Souza, J. G. de, Morais, K. L. P., Anglés-Cano, E., Boufleur, P., Mello, E. S. de, Maria, D. A., et al. (2016). Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model. OncoTarget, 7( 38), 62255-62266. doi:10.18632/oncotarget.11555
NLM
Souza JG de, Morais KLP, Anglés-Cano E, Boufleur P, Mello ES de, Maria DA, Origassa CST, Zampolli H de C, Câmara NOS, Berra CM, Bosch RVB, Chudzinski-Tavassi AM. Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model [Internet]. OncoTarget. 2016 ; 7( 38): 62255-62266.[citado 2025 out. 26 ] Available from: https://doi.org/10.18632/oncotarget.11555
Vancouver
Souza JG de, Morais KLP, Anglés-Cano E, Boufleur P, Mello ES de, Maria DA, Origassa CST, Zampolli H de C, Câmara NOS, Berra CM, Bosch RVB, Chudzinski-Tavassi AM. Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model [Internet]. OncoTarget. 2016 ; 7( 38): 62255-62266.[citado 2025 out. 26 ] Available from: https://doi.org/10.18632/oncotarget.11555
Artigo de periodico
Laminin-111 peptide C16 regulates invadopodia activity of malignant cells through β1 integrin, Src and ERK 1/2 (2016)
Siqueira, Adriane Sousa de; Pinto, Monique Rodrigues Pereira; Cruz, Mário Costa; Smuczek, Basilio; Cruz, Karen Steponavicius Piedade; Barbuto, José Alexandre Marzagão ; Hoshino, Daisuke; Weaver, Alissa M; Freitas, Vanessa Morais ; Jaeger, Ruy Gastaldoni
Fonte: OncoTarget. Unidade: ICB
Assuntos: PEPTÍDEOS, INTEGRINAS, CARCINOMA DE CÉLULAS ESCAMOSAS, FIBROSSARCOMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SIQUEIRA, Adriane Sousa de et al. Laminin-111 peptide C16 regulates invadopodia activity of malignant cells through β1 integrin, Src and ERK 1/2. OncoTarget, v. 7, n. 30, p. 47904-4717, 2016Tradução . . Disponível em: https://doi.org/10.18632/oncotarget.10062. Acesso em: 26 out. 2025.
APA
Siqueira, A. S. de, Pinto, M. R. P., Cruz, M. C., Smuczek, B., Cruz, K. S. P., Barbuto, J. A. M., et al. (2016). Laminin-111 peptide C16 regulates invadopodia activity of malignant cells through β1 integrin, Src and ERK 1/2. OncoTarget, 7( 30), 47904-4717. doi:10.18632/oncotarget.10062
NLM
Siqueira AS de, Pinto MRP, Cruz MC, Smuczek B, Cruz KSP, Barbuto JAM, Hoshino D, Weaver AM, Freitas VM, Jaeger RG. Laminin-111 peptide C16 regulates invadopodia activity of malignant cells through β1 integrin, Src and ERK 1/2 [Internet]. OncoTarget. 2016 ; 7( 30): 47904-4717.[citado 2025 out. 26 ] Available from: https://doi.org/10.18632/oncotarget.10062
Vancouver
Siqueira AS de, Pinto MRP, Cruz MC, Smuczek B, Cruz KSP, Barbuto JAM, Hoshino D, Weaver AM, Freitas VM, Jaeger RG. Laminin-111 peptide C16 regulates invadopodia activity of malignant cells through β1 integrin, Src and ERK 1/2 [Internet]. OncoTarget. 2016 ; 7( 30): 47904-4717.[citado 2025 out. 26 ] Available from: https://doi.org/10.18632/oncotarget.10062
Artigo de periodico
Multipolar mitosis and aneuploidy after chrysotile treatment: a consequence of abscission failure and cytokinesis regression (2016)
Cortez, Beatriz Araujo; Teixeira, Paula Rezende; Redick, Sambra; Doxsey, Stephen; Machado-Santelli, Glaucia Maria
Fonte: OncoTarget. Unidade: ICB
Assuntos: ASBESTO, MITOSE, NEOPLASIAS PULMONARES, CARCINOMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CORTEZ, Beatriz Araujo et al. Multipolar mitosis and aneuploidy after chrysotile treatment: a consequence of abscission failure and cytokinesis regression. OncoTarget, v. 7, n. 8, p. 8979-8992, 2016Tradução . . Disponível em: https://doi.org/10.18632/oncotarget.6924. Acesso em: 26 out. 2025.
APA
Cortez, B. A., Teixeira, P. R., Redick, S., Doxsey, S., & Machado-Santelli, G. M. (2016). Multipolar mitosis and aneuploidy after chrysotile treatment: a consequence of abscission failure and cytokinesis regression. OncoTarget, 7( 8), 8979-8992. doi:10.18632/oncotarget.6924
NLM
Cortez BA, Teixeira PR, Redick S, Doxsey S, Machado-Santelli GM. Multipolar mitosis and aneuploidy after chrysotile treatment: a consequence of abscission failure and cytokinesis regression [Internet]. OncoTarget. 2016 ; 7( 8): 8979-8992.[citado 2025 out. 26 ] Available from: https://doi.org/10.18632/oncotarget.6924
Vancouver
Cortez BA, Teixeira PR, Redick S, Doxsey S, Machado-Santelli GM. Multipolar mitosis and aneuploidy after chrysotile treatment: a consequence of abscission failure and cytokinesis regression [Internet]. OncoTarget. 2016 ; 7( 8): 8979-8992.[citado 2025 out. 26 ] Available from: https://doi.org/10.18632/oncotarget.6924
Artigo de periodico
Modular transcriptional repertoire and MicroRNA target analyses characterize genomic dysregulation in the thymus of Down syndrome infants (2016)
Moreira-Filho, Carlos Alberto; Bando, Silvia Yumi; Bertonha, Fernanda Bernardi; Silva, Filipi Nascimento; Costa, Luciano da Fontoura ; Ferreira, Leandro Rodrigues; Furlanetto, Glaucio; Chacur, Paulo; Zerbini, Maria Claudia Nogueira; Carneiro-Sampaio, Magda
Fonte: OncoTarget. Unidades: FM, IFSC
Assuntos: REDES COMPLEXAS, SIMETRIA, MEDIDAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MOREIRA-FILHO, Carlos Alberto et al. Modular transcriptional repertoire and MicroRNA target analyses characterize genomic dysregulation in the thymus of Down syndrome infants. OncoTarget, v. 7, n. 7, p. 7497-7533, 2016Tradução . . Disponível em: https://doi.org/10.18632/oncotarget.7120. Acesso em: 26 out. 2025.
APA
Moreira-Filho, C. A., Bando, S. Y., Bertonha, F. B., Silva, F. N., Costa, L. da F., Ferreira, L. R., et al. (2016). Modular transcriptional repertoire and MicroRNA target analyses characterize genomic dysregulation in the thymus of Down syndrome infants. OncoTarget, 7( 7), 7497-7533. doi:10.18632/oncotarget.7120
NLM
Moreira-Filho CA, Bando SY, Bertonha FB, Silva FN, Costa L da F, Ferreira LR, Furlanetto G, Chacur P, Zerbini MCN, Carneiro-Sampaio M. Modular transcriptional repertoire and MicroRNA target analyses characterize genomic dysregulation in the thymus of Down syndrome infants [Internet]. OncoTarget. 2016 ; 7( 7): 7497-7533.[citado 2025 out. 26 ] Available from: https://doi.org/10.18632/oncotarget.7120
Vancouver
Moreira-Filho CA, Bando SY, Bertonha FB, Silva FN, Costa L da F, Ferreira LR, Furlanetto G, Chacur P, Zerbini MCN, Carneiro-Sampaio M. Modular transcriptional repertoire and MicroRNA target analyses characterize genomic dysregulation in the thymus of Down syndrome infants [Internet]. OncoTarget. 2016 ; 7( 7): 7497-7533.[citado 2025 out. 26 ] Available from: https://doi.org/10.18632/oncotarget.7120

Unidades USP

ReP

Filtros

Departamento

Autores

Autores USP

Assuntos

Agência de fomento

Indexado em

Afiliação dos autores externos não normalizada

País das instituições de afiliação dos autores externos